Repligen Co. (NASDAQ:RGEN) Receives Average Rating of “Buy” from Brokerages

Repligen Co. (NASDAQ:RGEN) has earned an average recommendation of “Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $97.50.

RGEN has been the subject of a number of recent analyst reports. BidaskClub upgraded Repligen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, July 27th. HC Wainwright upgraded Repligen from a “neutral” rating to a “buy” rating and set a $110.00 price objective for the company in a research note on Monday, July 22nd. Craig Hallum reaffirmed a “buy” rating and set a $108.00 target price (up previously from $80.00) on shares of Repligen in a report on Monday. ValuEngine downgraded Repligen from a “strong-buy” rating to a “buy” rating in a report on Thursday. Finally, Zacks Investment Research raised Repligen from a “hold” rating to a “strong-buy” rating and set a $102.00 target price on the stock in a report on Thursday, July 18th.

In related news, Director Glenn L. Md Cooper sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 23rd. The stock was sold at an average price of $66.94, for a total value of $334,700.00. Following the sale, the director now owns 35,975 shares of the company’s stock, valued at approximately $2,408,166.50. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Karen A. Dawes sold 1,295 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The stock was sold at an average price of $77.35, for a total value of $100,168.25. Following the completion of the sale, the director now directly owns 118,329 shares in the company, valued at approximately $9,152,748.15. The disclosure for this sale can be found here. Company insiders own 1.70% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in RGEN. Geode Capital Management LLC lifted its holdings in shares of Repligen by 10.8% in the 4th quarter. Geode Capital Management LLC now owns 453,699 shares of the biotechnology company’s stock worth $23,927,000 after purchasing an additional 44,186 shares during the last quarter. Two Sigma Advisers LP acquired a new stake in Repligen in the 4th quarter valued at approximately $522,000. Bank of America Corp DE increased its position in Repligen by 50.7% in the 4th quarter. Bank of America Corp DE now owns 106,743 shares of the biotechnology company’s stock valued at $5,629,000 after acquiring an additional 35,909 shares during the period. Metropolitan Life Insurance Co. NY increased its position in Repligen by 348.0% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 12,565 shares of the biotechnology company’s stock valued at $663,000 after acquiring an additional 9,760 shares during the period. Finally, Municipal Employees Retirement System of Michigan acquired a new stake in Repligen in the 4th quarter valued at approximately $595,000. 85.61% of the stock is currently owned by institutional investors and hedge funds.

NASDAQ RGEN traded down $2.31 during mid-day trading on Wednesday, reaching $88.30. 23,337 shares of the company’s stock traded hands, compared to its average volume of 636,756. Repligen has a 1-year low of $47.23 and a 1-year high of $99.25. The firm’s fifty day simple moving average is $85.77. The company has a current ratio of 2.18, a quick ratio of 1.84 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $4.28 billion, a P/E ratio of 120.68, a price-to-earnings-growth ratio of 5.45 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Thursday, August 1st. The biotechnology company reported $0.31 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.06. Repligen had a return on equity of 7.66% and a net margin of 11.42%. The firm had revenue of $70.70 million during the quarter, compared to analyst estimates of $65.47 million. During the same quarter last year, the firm earned $0.14 EPS. Repligen’s quarterly revenue was up 48.1% on a year-over-year basis. Equities analysts expect that Repligen will post 0.97 earnings per share for the current year.

About Repligen

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

See Also: Preferred Stock

Analyst Recommendations for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.